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The purpose of this review is to analyse current options for fertility preservation in young 
women with breast cancer (BC). Considering an increasing number of BC survivors, owing to 
improvements in cancer treatment and delaying of childbearing, fertility preservation 
appears to be an important issue. Current fertility preservation options in BC survivors range 
from well-established standard techniques to experimental or investigational interventions. 
Among the standard options random-start ovarian stimulation protocol represents a new 
technique, which significantly decreases the total time of the in vitro fertilisation cycle. 
However, in patients with oestrogen-sensitive tumours, stimulation protocols using 
aromatase inhibitors are currently preferred over tamoxifen regimens. Cryopreservation of 
embryos and oocytes are nowadays deemed the most successful techniques for fertility 
preservation in BC patients. GnRH agonists during chemotherapy represent an experimental 
method for fertility preservation due to conflicting long-term outcome results regarding its 
safety and efficacy. Cryopreservation of ovarian tissue, in vitro maturation of immature 
oocytes and other strategies are considered experimental and should only be offered within 
the context of a clinical trial. An early pretreatment referral to reproductive endocrinologists 
and oncologists should be suggested to young BC women at risk of infertility, concerning the 
risks and benefits of fertility preservation options.       
 
 
 
Introduction 
Fertility preservation in breast cancer (BC) patients makes sense, since women who got 
pregnant following BC had a 41% reduced risk of death compared to women who did not get 
pregnant (PRR: 0.59), suggesting that pregnancies do not have an adverse effect on the 
outcome of BC. Therefore, BC survivors should not be denied the opportunity of future 
conception [1]. Although most physicians recommend that pregnancy should be delayed by 2 to 3 
years after BC, in early BC patients younger than 45 years of age, pregnancy that occurs at 
least 10 months after diagnosis does not jeopardize the prognosis and may actually confer 
significant survival benefit [2]. An increase in the incidence rate of BC in European women in 
their 20s and 30s has recently been reported, with the mean annual changes during the 
1995-2006 decade being 1.032 and 1.014, in women aged 20-29 and 30-39 years, 
respectively [3]. In the USA, the incidence of BC increased in 25- to 39-year-old women from 
1.53 per 100,000 in 1976 to 2.90 per 100,000 in 2009 [4]. However, the mortality rate in 
women under the age of 40 with BC has steadily been decreasing since the mid 80s, due to 
earlier diagnosis and recent advances in treatment [5].  
In the past decades more women have delayed childbearing until their 30s or later 
for different reasons. Unfortunately, there appears to be an increased BC risk with advancing 
maternal age at first childbirth: a 3,7 relative risk in women with an estimated first median 
age of 41 years, compared with those with an estimated first birth age of 23 years [6]. 
Consequently, a greater number of BC survivors are faced with reproductive concerns prior 
to completing their family. In a pilot survey of survivors’ attitudes, 76% of young childless 
women with cancer intended to have a child in the future and 35% of the survivors who 
already had at least one child wanted to have another [7].  
Therefore, international recommendations have been suggested regarding fertility 
preservation in these patients with cancer desiring pregnancy. The Update Panel of the 
American Society of Clinical Oncology (ASCO) recommends to health care providers, including 
oncologists, urologists, haematologists, surgeons and reproductive specialists to inform patients 
regarding potential threats to fertility, as early as possible, to allow the widest array of 
options for fertility preservation [8]. The European Society Medical Oncology (ESMO) Clinical 
Practice Guidelines recommended that young women desiring pregnancy following cancer 
diagnosis should be counselled on available fertility preserving options soon after diagnosis, 
to allow prompt referral to fertility specialists [9]. The First international consensus 
guidelines suggest that young women with BC, faced with specific physical, psychosocial and 
sexual issues, should address themselves to a multidisciplinary team of providers, including 
oncologists, breast nurses, social workers, psycho-oncologists, gynaecologists and fertility 
experts [10]. Although Anti-Mullerian hormone may be a useful marker of ovarian reserve 
before gonadotrophin administration in young BC patients at risk for poor-response or no 
response to ovarian stimulation, its clinical role in early BC and in predicting treatment-
induced infertility needs to be defined [11].  
Currently available options to BC patients protecting their fertility range from well-
established standard techniques, such as ovarian stimulation for in vitro fertilisation (IVF) 
and embryo/oocyte cryopreservation, to investigational or experimental interventions as 
are, ovarian tissue cryopreservation, in vitro maturation (IVM) of immature oocytes and 
ovarian suppression with gonadotrophin releasing hormone (GnRH) agonists during 
chemotherapy [12]. Although many young women (68%) with BC do discuss fertility issues 
with their physicians before starting therapy and more than a half (51%) are concerned 
about becoming infertile after treatment, only a minority of women (10%) chooses to pursue 
available fertility preservation strategies [13]. Therefore, more efforts are necessary in order 
to achieve better patient understanding, to improve physicians, ability to convey of fertility 
preservation possibilities to all women of reproductive age with cancer and to encourage 
participation in informed decisions about their therapeutic strategy and future reproductive 
ability [14].  
As the number of younger BC patients increases the aim of this review is to 
summarize the current knowledge on various fertility preservation options and consequently 
improve the communication between health care providers and patients about their 
benefits and disadvantages. 
 
Ovarian stimulation  
Ovarian stimulation for oocyte/embryo cryopreservation is currently the best established 
and the most preferred method for fertility preservation in BC patients. Although most 
young patients may conceive spontaneously, it is important to choose the appropriate 
ovulation induction protocol, because these patients have only one opportunity to undergo 
a single cycle of IVF before starting oncologic treatment. In most cases, ovarian stimulation 
protocols using gonadotrophins with GnRH antagonists and GnRH agonists for trigger should 
be preferred in fertility preservation cycles due to time restraints and the risk of ovarian 
hyperstimulation syndrome (OHSS) [15]. Instead of traditional ovarian stimulation with 
GnRH agonists, currently GnRH antagonists are routine practice in fertility preservation. 
Advances have been made from GnRH agonists to GnRH antagonists and to random start 
stimulation, in order to minimize the time from patient presentation to oocyte retrieval [16]. 
However, in cases of BC with oestrogen positive receptors several alternative and potentially 
safer protocols have been introduced using tamoxifen and aromatase inhibitors [17].  
Conventional-start ovarian stimulation with GnRH antagonists can be used in a fixed 
manner or in a flexible manner during the gonadotrophin stimulation. Although this 
approach still requires awaiting spontaneous menses, it decreases the interval to oocyte 
retrieval compared to traditional stimulation protocols. Alternatively, the administration of 
GnRH antagonists in the midluteal phase results in quicker initiation of gonadotrophins and 
GnRH antagonists, further reducing delays for BC treatment. Nevertheless, adhering to the 
conventional-start antagonist protocols could result in significant delay of cancer treatments 
[16,18]. 
Random-start ovarian stimulation protocol represents a new fertility preservation 
technique, when waiting for the next menstrual period to start the ovulation induction is not 
advisable, due to the urgency of the cancer treatment. It has been proposed to start in the 
late follicular phase or the luteal phase following spontaneous luteinizing hormone (LH) 
surge or after the ovulation induction with human chorionic gonadotrophin (hCG) or a GnRH 
agonist. Therefore, random-start ovarian stimulation provides a significant advantage by 
decreasing the total time of the IVF cycle, without compromising the oocyte yield and 
maturity before the cancer treatment. Since oocytes can be obtained before cancer 
treatment irrespective of the phase of the menstrual cycle, both random-start ovarian 
stimulation protocols are as effective as conventional-start regimens in the early follicular 
phase [17,19]. The average number of oocytes retrieved was similar between the groups 
(12.5 vs.15) [16]. 
Moreover, double ovarian stimulations during the follicular and luteal phases in the 
same menstrual cycle, provide more opportunities for retrieving more oocytes, in a short 
period of time in poor responders and newly diagnosed cancer patients needing fertility 
preservation. The primary outcome measured was the number of oocytes retrieved: stage one 1.7 
and stage two 3.5. Out of 167 oocytes collected 26 succeeded in producing one to six viable embryos 
cryopreserved for later transfer [20]. In assesing the clinical pregnancy rate in recipients of 
embryos from the same oocyte donor, obtained after ovarian stimulation initiated on day 2 
or day 15 of the menstrual cycle, no differences were noted in pregnancy rates (62.5% vs. 
58.3%) after both types of ovarian stimulation. Good pregnancy rates achieved on day 15 of the 
cycle may be useful information for patients with cancer undergoing fertility preservation 
[21].  
In the evaluation of the safety and efficacy of tamoxifen co-administration during 
conventional ovarian stimulation for fertility-preservation in BC patients, it was found that 
the high serum estradiol levels should be considered safe and that tamoxifen does not 
interfere with IVF results [22]. Aromatase inhibitors significantly reduce plasma oestrogen 
levels by competitively suppressing the activity of the aromatase enzyme. The third 
generation aromatase inhibitor, letrozole, is a drug of choice for the treatment of BC in 
women with oestrogen positive receptors and has recently been introduced as a new option 
for ovulation induction [23]. Furthermore, the use of aromatase inhibitors with 
gonadotrophins represents a safe and effective protocol for fertility preservation for women 
with BC [24]. Moreover, in patients requiring emergency fertility preservation, ovarian 
stimulation with the use of letrozole 2.5 mg/d, gonadotrophins, GnRH antagonists and hCG 
can be started at a random cycle date without compromising fertilization rates [25]. The use 
of GnRH agonist trigger instead of hCG, reduces oestrogen exposure and improves cycle 
outcomes, by increasing the yield of mature oocytes and embryos as well as decreasing the 
incidence of OHSS during ovarian stimulation with letrozole (5 mg/d) and gonadotrophins 
[26]. The largest prospective data with the longest follow up on the safety of ovarian 
stimulation with letrozole and gonadotrophins for fertility preservation suggests that it is 
unlikely to cause a substantially increased recurrence risk in BC patients, even in women 
who have not yet undergone breast surgery [27]. However, anastrozole, another third-
generation aromatase inhibitor has a minimal suppressive effect on rising estradiol levels 
and its use is not recommended in fertility preservation cycles of oestrogen-sensitive cancer 
patients [28].  
 
Embryo and oocyte cryopreservation 
Embryo cryopreservation is the most established technique for fertility preservation for 
women with available partner or for women using donor semen, which  combines ovarian 
stimulation, oocyte retrieval and IVF. It usually takes 2–5 weeks and is therefore not 
applicable to patients who cannot delay BC treatment. According to Society for Assisted 
Reproductive Technologies, the current live-birth rate per transfer using frozen-thawed 
embryos in women under 35 years across the U.S. is 35.6%. [15,29,30]. The main methods of 
embryo cryopreservation are slow freezing and vitrification, with the latter gaining more 
popularity in recent years. Both vitrification methods (Irvine and Vitrolife) are more efficient 
(89.4% vs. 87.6%) than slow freezing (63.8%) for cryopreservation of human cleavage stage 
embryos in terms of post-warming survival rate [31]. Furthermore, vitrification of cleavage 
stage embryos yields a significantly better cycle outcome than slow freezing 
cryopreservation, according to the clinical pregnancy rate (20% vs.11.9%, respectively) [32]. 
The effectiveness of cryopreservation techniques is best evidenced by the success of 
cryopreserved embryos and the IVF outcome of frozen-thaw cycles, which have shown a 
satisfactory live birth rate (22%) in cancer patients for fertility preservation who have 
returned to use their embryos, over a 15-year period of follow-up (1996–2011) [33]. 
 Freezing of mature oocytes for fertility preservation is an alternative to embryo 
cryopreservation and it is the preferred strategy regardless of the presence or absence of a 
partner [34]. The patient has to undergo ovarian stimulation and egg retrieval to obtain 
oocytes before chemotherapy, in order to avoid fertilizing a damaged egg and does not 
require IVF. Unlike embryo freezing, oocyte cryopreservation is an alternative option that 
can avoid ethical, religious and legal concerns [35]. Although human oocytes are extremely 
sensitive to temperature changes, cryoprotectants and ice formation, vitrification is more 
effective than slow cooling, as shown by higher survival rate and spindle assessment. Since 
embryos resulting from vitrified oocytes have significantly enhanced clinical pregnancy rates 
(38%), compared with embryos resulting from slow-rate freezing oocytes (13%), 
vitrification/warming is currently the most efficient method of oocyte cryopreservation 
[36,37]. These results were confirmed recently showing that vitrification success rates are 
superior to slow freezing, while the success rates of both techniques match those of fresh 
embryo transfer. However, the success rates with either technique tend to meaningfully 
decline after the age of 36 [38]. It should be noted that vitrification, a relatively recent 
clinical programme, has yielded over 1000 infants born worldwide and these figures are 
constantly increasing [39]. Consequently, in 2012, the American Society of Reproductive 
Medicine removed oocyte freezing from the experimental category for the patients who are unable 
to cryopreserve embryos and facing infertility due to gonadotoxic therapies, but not for the sole 
purpose of circumventing reproductive aging in healthy women [40]. 
Cryopreservation of immature oocytes represents an attractive alternative to 
cryopreservation of mature oocytes, because it does not require ovarian stimulation for BC patients 
with oestrogen sensitive tumours or who cannot delay chemotherapy. Following retrieval, immature 
oocytes can be cryopreserved either before or after IVM, which is mostly used in combination with 
other strategies rather than alone. Immature oocytes survive cryopreservation better than 
mature oocytes and after thawing these oocytes can be successfully matured in vitro and fertilized. 
Since the efficacy of cryopreservation of immature oocytes is very low, it still  remains an 
experimental option for fertility preservation [29,41-43]. However, IVM of immature oocytes 
prior to cryopreservation optimizes the reproductive potential because combined survival 
and maturation were significantly higher in fresh oocytes undergoing IVM (63.8%), 
compared with the postthaw IVM group (33.3%) [44].  Additionally, the combination of 
ovarian tissue cryopreservation with immature oocyte collection from the tissue followed by 
oocyte vitrification via IVM, represents another promising approach to fertility preservation 
in young women with cancer [45].   
 
 
 
 
Ovarian tissue cryopreservation 
According to a group of experts ovarian tissue preservation is the only fertility preservation 
possibility for prepubertal girls with cancer [34]. For BC patients who require urgent cancer 
treatment such as neo-adjuvant chemotherapy, ovarian tissue cryopreservation for future 
autotransplantation should be considered as the only fertility preservation option [46]. 
Ovarian tissue can be extracted by laparoscopy in order to harvest the ovarian cortex 
containing a lot of primordial follicles that are relatively resistant to freeze-thaw injury. It  
appears that the slow freezing technique makes the oocyte and granulosa cells more 
vulnerable whereas vitrification is a safer and more efficient method. Autotransplantation of 
the cortical strips after BC treatment is typically performed orthotopically by laparoscopy 
into the ovary or the pelvic peritoneum allowing natural conception [47]. The age limit for 
cryopreservation is a crucial factor because the chance of restoring the ovarian function is 
closely correlated to the number of follicles in the ovarian graft. Women should be up to the 
age of 35 to 37 because follicular density is still sufficient, otherwise the chance of 
pregnancy is low [48]. Worldwide, at least twenty two singletons and two sets of twins have 
so far been born with a total of 26 healthy children born as a result of orthotopic 
retransplantation of cryopreserved ovarian tissue [49]. In appears that the success rate may 
be higher in experienced transplantation centres because following transplantation into the 
peritoneum delivery rates were in 23% of cases and following overnight transportation of 
ovarian tissue delivery rates were up to 29% [50]. Unfortunately, the future of heterotopic 
grafting of cryopreserved ovarian tissue subcutaneously to the forearm or the suprapubic 
region and its clinical practicability for fertility preservation is still debatable [51].     
 
However, in women with Breast cancer antigen (BRCA) mutation–positive BC there 
are safety concerns considering fertility preservation. An early oophorectomy may be 
recommended to cryopreserve ovarian tissue of these patients before their risk for ovarian 
cancer increases with age. It appears that ovarian tissue reimplantation (rather than 
cryopreservation) is not considered to be a safe procedure in BRCA mutation carriers nor in 
advanced stage BC nor in invasive lobular BC. The use of preimplantation genetic diagnosis 
during IVF may be acceptable despite psychosocial and emotional difficulties [52]. Therefore, 
ovarian tissue transplantation remains an experimental fertility preservation approach due 
to insufficient data on the efficacy, safety and the reproductive outcomes – a possibility for 
patients carefully selected by centres with the necessary laboratory and surgical expertise 
[53]. 
 
Ovarian suppression with GnRH analogues 
Although adjuvant chemotherapy with tamoxifen have  conferred significant improvements 
in the overall survival of young BC patients, long-term adverse effects of cytotoxic 
treatment, such as premature ovarian failure (POF) and infertility have become increasingly 
important. A potential fertility preservation strategy may be administration of GnRH agonists 
before and during adjuvant chemotherapy. However, the results of a recent meta-analysis, 
suggest that concurrent use of GnRH agonists and chemotherapy in BC patients who did not 
use tamoxifen after chemotherapy, may not preserve ovarian function [54]. Therefore, 
ovarian suppression with GnRH agonists during chemotherapy has been considered 
experimental, although several recent studies offer both safety and efficacy for the use of 
GnRH agonists [55]. Adjuvant therapy with GnRH agonists alone or in combination with 
tamoxifen, produces results at least similar to those obtained with the different 
chemotherapy protocols in patients with hormone receptor-positive BC, with respect to 
overall survival. Therefore, it is advisable to choose GnRH agonist with tamoxifen for 
oestrogen receptor-positive BC patients, whereas for hormone receptor-negative women 
chemotherapy is possible to lead to reduction of the risk of recurrence. However, before 
asserting that adjuvant endocrine therapy produces similar results to adjuvant 
chemotherapy, it would be useful to assess the lymph node status, mitotic index and HER2 
expression which may also influence the prognosis of BC  [56]. The annual report of the 
ASCO about the Clinical cancer advances in 2015, suggests good news for women with early-
stage BC, desiring to have a child after BC treatment. Although POF is a common adverse 
effect in young women undergoing chemotherapy, new studies represent a promising way 
to preserve fertility, improve the long-term outcome results and the safety issue in BC 
patients. It appears that GnRH agonists temporarily shut down ovarian function, by 
introducing the patient in a postmenopausal state, protecting follicles and developing 
oocytes from chemotherapy damage in young women with BC [57]. In the first study, GnRH 
analogue administration with chemotherapy was associated with less POF and more 
pregnancies in premenopausal women with BC and hormone receptor–negative disease. 
Adding the hormone drug goserelin to standard chemotherapy cut the rate of POF from 22 
to 8%. After an extended follow-up period of 11,3 years the combination treatment 
approach resulted in successful pregnancies in 22 (88%) of the 25 women who attempted 
pregnancy, compared with 12 (67%) of 18 women who attempted pregnancy after receiving 
standard chemotherapy alone. The hormonal treatment did not increase the risk of 
miscarriage, pregnancy termination, or delivery complications and it even extended 
women's survival, compared with chemotherapy alone [58]. Another study reported 
similarly encouraging assesing results in mostly hormone receptor–positive BC, assessing the 
effect of triptorelin, on preventing POF in women with early-stage BC undergoing 
chemotherapy. After an average follow-up period of 7.3 years, there were eight pregnancies 
among the 148 women who received chemotherapy plus triptorelin with four pregnancies 
among the 133 women who received chemotherapy alone and triptorelin did not affect 
survival [59]. (Table 1) 
 
Other experimental strategies 
Significant progress has been made in the development of other improved methods for 
fertility preservation such as in vitro follicle maturation, isolation of primordial follicles with 
transplantation in scaffolds, the potential role of AS 101, S1P and imatinib, which may 
revolutionise fertility preservation practice. However, further technological advances and 
research are required before these strategies can be utilised therapeutically in humans [60-
64]. Ovarian tissue banking of thin cortical surface biopsies that contain predominantly 
primordial follicles is being increasingly offered to a variety of patients as a means of fertility 
preservation. The potential of this tissue could be realized by the development of in vitro 
systems, to support complete growth from the early primordial stages through to maturity. 
However, complete oocyte development in vitro from the primordial stage has been 
achieved only in mice [60]. Comparing macroporous alginate scaffolds with Matrigel for 
culturing frozen-thawed human primordial follicles in organ culture, it was shown that three 
dimensional alginate scaffolds are a promising putative in vitro technology for developing 
human primordial follicles [61]. Although cyclophosphamide activates the growth of the 
quiescent primordial follicles in mice and leads to loss of ovarian reserve, coadministration 
of an immunomodulator, AS101, reduces follicle activation, thereby increasing follicle 
reserve and rescuing fertility after cyclophosphamide and increasing the efficacy of 
cyclophosphamide against BC cell lines. Therefore, AS101 may be useful as an ovarian-
protective agent, which may be able to preserve fertility in female cancer patients [62]. 
Furthermore, Sphingosine-1-phosphate (S1P), a ceramide-induced death pathway inhibitor, 
can prevent cyclophosphamide or doxorubicin induced apoptotic follicle death in human 
ovarian xenografts. Therefore, S1P and its future analogues may be desirable for preserving 
fertility for patients undergoing chemotherapy [63]. Although two commonly used 
chemotherapeutic agents (cisplatin and doxorubicin) induce follicle loss in a markedly 
different pattern, imatinib mesylate provides selective protection only against cisplatin. 
Therefore, any treatment designed to protect the adverse effects on the ovary needs to be 
specific to the drug regimen to which the patient is exposed [64]. 
 
Conclusions 
Fertility is a major concern for young BC patients and information about fertility preservation 
options is of crucial importance. Random-start ovarian stimulation protocol represents a 
commendable technique, advisable in cases of urgent cancer treatment. In patients with 
oestrogen-sensitive tumours, stimulation protocols using letrozole are currently preferred 
over tamoxifen regimens. The most successful techniques for fertility preservation in BC 
patients are cryopreservation of embryos and oocytes. Ovarian suppression with GnRH 
agonists during chemotherapy represents an experimental method for fertility preservation 
due to conflicting results regarding its efficacy. Cryopreservation of ovarian tissue, IVM of 
immature oocytes and other strategies are considered investigational or experimental and 
should only be offered within the context of a clinical trial. The patient′s future chance of 
pregnancy should be discussed within an interdisciplinary medical team, made up of 
oncologists and fertility specialists, early in the early pretreatment consultation. 
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Table 1 Comparison of characteristics and outcomes of commonly used fertility 
 preservation options in BC patients    preservation options in BC patients  
 
 
 
Fertility 
preservation 
options 
/Characteristics 
 
Studies 
 
Advantages Disadvantages Live-birth rates 
Embryo 
cryopreservation  
Bedoschi G et al. [15]  
Kim SS et al. [29]  
Lawrenz B et al. [30] 
Barcroft J et al. [33] 
 
 
Most established and 
successful technique  
Pregnancy outcome  
similar or  higher than 
with fresh embryo transfer 
 
Ovarian stimulation, oocyte 
retrieval and IVF 
Required time 2–5 weeks 
Need a partner or donor 
Delay of treatment required 
Risk of OHSS 
22%-35,6%  
Mature oocytes 
cryopreservation  
Konc J et al.  [35] 
Smith GD et al.  [37] 
Cil AP et al. [38] 
Rodriguez-Wallberg KA et 
al. [39] 
 
Alternative to embryo 
freezing 
Partner not required 
No ethical, religious and 
legal concerns 
Over 1000 babies born 
wotldwide  
Not for the sole purpose in 
healthy women 
Ovarian stimulation, oocyte 
retrieval 
Cellular damage of oocytes 
Risk of OHSS 
Lower success rates after the 
age of 36 
13%-38% 
Cryopreservation 
and 
transplantation of 
ovarian tissue 
Mathias FJ et al. [47]  
von Wolff M  et al.   [48] 
Macklon KT et al. [49] 
Liebenthron JR et al. [50] 
Rodriguez-Wallberg KA et 
al. [52] 
Urgent BC treatment  
Prepubertal girls with 
cancer 
Partner not required 
Overnight tissue 
transportation to  
experienced 
transplantation centres  
26 healthy children born 
Laparoscopic removal with 
orthotopic retransplantation 
and heterotopic grafting of 
ovarian tissue 
Women should be up to the 
age of 35 to 37 
Risk of reintroduction 
cancerous cells 
Experimental option 
10%-29% 
Ovarian 
suppression with 
GnRH analogues 
during 
chemotherapy 
Vitek WS et al. [54] 
Franco JG et al. [56] 
Masters GA et al. [57] 
Moore HCF et al. [58] 
Lambertini M et al. [59] 
  
 
Reduction in the rate of 
POF from 22 to 8% 
Increase in pregnancy 
rates from 11 to 21%  
Non-invasive strategy 
No operation required 
No preservation of ovarian 
function 
Controversial results 
regarding efficacy and safety  
Experimental method  
 
18% 
